THEY TRUST US

OUR CLIENTS

We started operations in 2019. Despite the few months we have been in business and the particular environment we all are in, leading pharma corporations have already experienced the value of our insights.  
pfizer.png
greenstone.png
regeneron.jpeg
boehringer ingelheim.png
mylan.jpg
sunonvon.png
Acadia.jpg
Gelesis.jpg
Pre-launch Study Evaluations gave us the insights that informed Phase 3 study design in time for us to include critical payer endpoints.
With a second indication on the horizon, a therapeutic class Drug Monograph Analysis revealed several unexpected perspectives that we leveraged to protect access.
Pre-launch competitive Label Comparison enabled us to prioritize our label negotiations to ensure our payer value was well represented at launch.
When we launched our small KAM team, we targeted Hospital System panelists to garner system-specific product insights that drove segmentation and prioritization of KAM targeting.
We bought a Rapid Survey subscription so that we can put out fires quickly based on feedback from our panelists whenever we need it!
A Formulary Insights Direct Inquiry provided us with the payer insights we needed to make a go or no-go decision on several planned product strategies, based on their expected access impact, quickly enhancing our product access and performance.
Formulary Insights guarantees the most authentic and reliable payer insights available.

Are you ready to ask all your questions to current P&T members?